Ipamorelin Dosage and Protocol Guide: Injection, Timing, and Cycle (2026)

Executive Summary

Ipamorelin dosage and protocol are the most-searched questions for anyone prescribed this growth hormone peptide — because while ipamorelin's mechanism is well-established, guidance on exactly how to take it (how much, when, how often, and for how long) is inconsistent online. This guide provides a structured protocol breakdown: standard dose ranges, subcutaneous injection technique, timing rationale, cycle structure, stacking strategies with CJC-1295, and what labs to monitor.

Ipamorelin is a synthetic pentapeptide (5 amino acids) and growth hormone releasing peptide (GHRP). It selectively stimulates the pituitary gland to produce growth hormone (GH) by binding the ghrelin/GHS receptor (GHSR-1a) — without meaningfully elevating cortisol, prolactin, or ACTH, which distinguishes it from earlier GHRPs like GHRP-2 and GHRP-6. Because ipamorelin triggers a clean, selective GH pulse, it is considered one of the most favorable GHRPs available and is among the most commonly prescribed growth hormone secretagogues in US telehealth alongside CJC-1295 and sermorelin.

Important context: ipamorelin is not FDA-approved for adult GH optimization and is available only through licensed US compounding pharmacies via physician prescription. The dosing parameters below reflect commonly prescribed telehealth protocols as of 2026 — they are not a substitute for individualized clinical guidance. Use this guide alongside our provider comparison tool, ipamorelin vs CJC-1295 comparison, and CJC-1295 + ipamorelin stack protocol guide.

At-a-Glance Comparison

Standard ipamorelin dosing parameters by protocol type as of 2026. Individual dosing should be determined by a licensed prescribing provider based on age, IGF-1 levels, goals, and response.

Why Fasted Timing Is Non-Negotiable: GH Pulse Physiology

Ipamorelin's timing requirement is mechanistically grounded — not arbitrary. The GH pulse amplitude from each injection is directly influenced by the metabolic state at injection time. Buyers searching for ipamorelin dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Growth hormone and insulin are physiologically antagonistic: when blood glucose is elevated (post-meal), insulin rises and GH pulse amplitude is substantially blunted. Free fatty acids from recent food intake create a similar suppressive effect. This means an ipamorelin injection taken 30 minutes after a meal produces a fraction of the GH pulse of the same injection in a fully fasted state. The bedtime dosing protocol capitalizes on two compounding advantages: (1) the 2+ hour post-dinner fast that most people naturally achieve by bedtime puts them in a permissive metabolic state for GH release, and (2) the body's largest natural GH pulse occurs 60–90 minutes after sleep onset during slow-wave sleep — ipamorelin amplifies this pulse rather than creating a competing signal. For twice-daily protocols, the second injection on waking (before breakfast or coffee with cream) creates a second GH pulse in the early morning hours, which is when natural GH secretion is already elevated. A pre-workout dose (30–45 minutes before training) is used in some advanced protocols but requires training in a fasted or 2+ hour post-meal state — exercise independently stimulates GH, and ipamorelin amplifies this exercise-induced pulse. Key fasting rules: no food for 2+ hours before injection; no high-fat, high-carbohydrate, or high-sugar foods in the hour before; avoid caloric beverages. Black coffee and plain water are acceptable. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The most common reason ipamorelin protocols underperform is poor timing. Patients who inject immediately post-dinner or within 1 hour of a meal consistently see weaker IGF-1 responses on follow-up labs. If IGF-1 is flat at 6–8 weeks despite adequate dosing, timing is the first variable to audit before increasing dose. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Subcutaneous Injection Technique: Step-by-Step

Ipamorelin is administered exclusively via subcutaneous (SubQ) injection — not intramuscular. The injection delivers peptide into the fatty tissue layer just beneath the skin for gradual systemic absorption. Buyers searching for ipamorelin dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

What you need: reconstituted ipamorelin vial (refrigerated); insulin syringes — 27–31 gauge, 0.5 mL or 1 mL barrel; alcohol swabs; sharps disposal container. Reconstitution reference: a standard 5 mg vial reconstituted with 2 mL bacteriostatic water yields 2,500 mcg/mL. At 200 mcg per dose, that is 0.08 mL per injection — 25 doses per 5 mg vial. Store reconstituted vials refrigerated (2–8°C) and use within 30 days. Label the vial with reconstitution date. Step-by-step injection protocol: (1) Wash hands with soap and water for 20+ seconds before handling vial or syringe. (2) Wipe the vial top with an alcohol swab and allow to air dry 10 seconds. (3) Draw air into syringe equal to planned dose (e.g., 0.08 mL for 200 mcg at 2,500 mcg/mL), insert needle into vial, push the air in, then draw your dose. (4) Check for bubbles — flick the syringe and push the plunger slightly to eliminate air. (5) Select injection site — lower abdomen (2+ inches from navel), outer thigh, or upper arm (outer aspect). Rotate sites each injection to prevent lipohypertrophy. (6) Wipe the skin site with an alcohol swab and allow to dry 10 seconds (wet skin increases sting on insertion). (7) Pinch the skin to lift subcutaneous tissue, insert the needle at a 45° angle (or 90° if using very short needles with adequate subcutaneous tissue). (8) Inject slowly — steady pressure over 5–10 seconds; rapid injection increases discomfort. (9) Withdraw needle and apply gentle pressure with a swab. Do not rub — rubbing disperses the peptide unevenly. (10) Dispose of needle immediately in a sharps container. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Common mistakes: using an expired or improperly stored reconstituted vial (cloudy or particulate vials must be discarded); using needles larger than 27 gauge; injecting into the same site repeatedly without rotation; injecting post-meal. Never inject into a vein — the SubQ technique described avoids this by design. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Stacking Ipamorelin with CJC-1295: Two-Pathway Synergy

The CJC-1295 + ipamorelin stack is the most commonly prescribed growth hormone peptide combination in US telehealth — because the two peptides target different receptor pathways and produce synergistic, not merely additive, GH output. Buyers searching for ipamorelin dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Mechanism of synergy: ipamorelin (GHRP) binds the ghrelin receptor (GHSR-1a) and triggers GH pulse amplitude — the height of each GH spike. CJC-1295 (GHRH analogue) binds the GHRH receptor and primes the pituitary somatotrophs to respond more robustly to the GHRP signal — increasing both pulse amplitude and frequency. Published GHRH + GHRP combination research consistently shows GH output 2–4× higher than either peptide alone. CJC-1295 no-DAC vs with DAC — which to choose: CJC-1295 no-DAC (Mod GRF 1-29) has a short half-life (~30 minutes) and requires daily injection alongside ipamorelin — it produces clean, pulsatile GH release patterns closest to natural physiology and is the most commonly prescribed CJC-1295 variant in stack protocols. CJC-1295 with DAC has an extended half-life (~8 days) and is dosed 1–2× weekly, providing a sustained lower-amplitude GH elevation throughout the week rather than discrete pulses. It is easier to adhere to but less physiological. Some advanced protocols combine weekly DAC injections with daily ipamorelin for both basal elevation and pulse amplification. Standard stack dosing: ipamorelin 200–300 mcg + CJC-1295 no-DAC 100–200 mcg at bedtime, combined in a single syringe or injected separately at the same time. See our full CJC-1295 + ipamorelin stack protocol guide for complete dosing tables, results timeline, and cost breakdown. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: If your pharmacy compound label says 'CJC-1295' without specifying DAC status, confirm before setting your dosing frequency. CJC-1295 with DAC dosed daily creates cumulative GHRH receptor stimulation that can desensitize the receptor and push IGF-1 above the reference range. No-DAC requires daily dosing; DAC does not — these are not interchangeable. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Lab Monitoring: What to Test and When

IGF-1 is the primary clinical marker for ipamorelin protocol response. Without it, you cannot objectively assess whether the protocol is working or whether dose adjustment is needed. Buyers searching for ipamorelin dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Baseline labs before starting: IGF-1 (primary), fasting glucose, fasting insulin, CBC, CMP. Establishes your pre-treatment IGF-1 for response tracking and rules out contraindications (active malignancy, uncontrolled diabetes, active acromegaly). Weeks 6–8 follow-up: repeat IGF-1. On a standard 200–300 mcg ipamorelin protocol, expect a measurable IGF-1 rise — typically 30–80 ng/mL above baseline. If IGF-1 is flat, audit timing (fasted?), confirm peptide storage is correct (must be refrigerated post-reconstitution), and consider dose titration before attributing failure to the peptide. Cycle end (12–24 weeks): full panel repeat — IGF-1, fasting glucose, CBC, CMP. Most prescribers target IGF-1 in the upper-normal range for age (upper third of the age-adjusted reference range) — not above range. Supraphysiological IGF-1 adds risk and is unnecessary for wellness optimization goals. Signs of GH excess to monitor: water retention/edema, joint aches, carpal tunnel-type tingling or numbness, elevated fasting glucose, fatigue. These are rare at standard ipamorelin doses (vs. direct HGH) but warrant a dose review if they appear — contact your provider and repeat IGF-1. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Skipping the 6–8 week IGF-1 check is the single most common protocol error. Without it, patients run multi-month cycles without knowing if the peptide is working, miss dose titration opportunities, and — in rare cases — run IGF-1 above reference range without knowing. Any provider that does not require baseline and follow-up IGF-1 labs is not running a clinically responsible protocol. See our best peptide clinics 2026 guide for options with lab monitoring included. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

What to Expect: Timeline, Results, and Side Effects

Ipamorelin produces gradual, physiological improvements — not rapid drug-like effects. Understanding the realistic timeline sets expectations and prevents early abandonment of an effective protocol. Buyers searching for ipamorelin dosage usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Timeline of common effects: weeks 1–4 — the most consistent early signal is improved sleep quality (deeper sleep, more vivid dreams, better recovery sensation on waking). This is often the first reported subjective effect and is a positive indicator that GH pulsatility is increasing. Some users report mild initial side effects in the first 1–2 weeks (see below). Weeks 4–8: improved recovery between training sessions, mild reduction in muscle soreness, early subjective changes in body composition. These effects are real but subtle at this stage. Weeks 8–16: body composition changes become measurable — typically increased lean mass retention, gradual reduction in visceral and subcutaneous fat (particularly with adequate protein and resistance training). Energy, skin quality, and libido improvements are commonly reported in this window. 4–6 months: cumulative outcome of a full cycle. Most peer-reviewed data on GHRPs and growth hormone secretagogues used 3–6 month assessment periods. Common side effects: mild injection site reactions (redness, itching, minor swelling — typically resolve within 30–60 minutes, and often improve as you refine injection technique); transient flushing or warmth 5–10 minutes post-injection (common, not harmful); mild headache during the first 1–2 weeks of initiation (resolves spontaneously); slight drowsiness after bedtime injection (generally considered beneficial, reflects GH pulse onset aligning with sleep onset). Cost context: ipamorelin compounded through US telehealth typically runs $80–$250/month depending on dose, vial size, and provider — significantly less expensive than pharmaceutical HGH. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Serious adverse effects (significant joint pain, carpal tunnel syndrome, glucose intolerance, persistent edema) are associated with IGF-1 levels above the age-adjusted reference range and are rare at standard ipamorelin doses. Regular IGF-1 monitoring is the primary safeguard. If serious symptoms develop, contact your prescribing provider immediately and request an early IGF-1 lab. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

If you are considering ipamorelin for GH optimization, body composition, recovery, or longevity, the right first step is a licensed provider consultation with baseline IGF-1 labs. Our provider comparison tool helps you find telehealth clinics that prescribe ipamorelin with US-licensed compounding pharmacies, written protocols, and follow-up lab monitoring. Our best peptide clinics 2026 guide is a strong starting point for comparing your options.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

What is the standard ipamorelin dosage?

The most commonly prescribed ipamorelin dose is 200–300 mcg per injection, administered subcutaneously. New users often start at 100–150 mcg and titrate up based on IGF-1 response and tolerance. Most clinical benefit is captured at 200–300 mcg — doses above 400–500 mcg do not produce proportionally greater GH output.

How many times a day should I inject ipamorelin?

Once daily at bedtime is the standard starting protocol. More advanced protocols use twice daily (bedtime + morning fasted) or three times daily (adding a pre-workout dose). Each injection must be timed in a fasted state — at least 2 hours after the last meal — to maximize GH pulse amplitude.

When is the best time to take ipamorelin?

Bedtime is the optimal injection time for most users. It aligns the ipamorelin-induced GH pulse with the body's natural nocturnal GH surge during slow-wave sleep. If dosing twice daily, the second dose is taken immediately upon waking in a fully fasted state before breakfast.

Should ipamorelin be taken with or without food?

Always without food. Elevated blood glucose and free fatty acids after a meal blunt GH pulse amplitude significantly. Dose ipamorelin at a minimum of 2 hours after your last meal, or in a completely fasted state. Eating 30–60 minutes after injection is generally acceptable — the GH pulse will already be underway.

How long does an ipamorelin cycle last?

Standard cycles are 3–6 months, followed by a 4–8 week break. Some prescribers use year-round dosing with periodic breaks. IGF-1 should be checked at 6–8 weeks into the cycle and at cycle completion to assess response and guide continuation.

Is ipamorelin better combined with CJC-1295?

Yes — ipamorelin and CJC-1295 are synergistic. CJC-1295 (a GHRH analogue) primes the pituitary through the GHRH receptor, while ipamorelin triggers the GH pulse through the ghrelin receptor. Combined, GH output is 2–4× higher than either alone. The CJC-1295 no-DAC + ipamorelin daily bedtime combination is the most commonly prescribed growth hormone secretagogue stack in US telehealth.

What's the difference between CJC-1295 no-DAC and CJC-1295 with DAC when stacking with ipamorelin?

CJC-1295 no-DAC (Mod GRF 1-29) has a short half-life and requires daily injection alongside ipamorelin — producing discrete, pulsatile GH release patterns. CJC-1295 with DAC has an ~8-day half-life and is dosed 1–2× weekly, providing sustained basal GH elevation. Most protocols start with no-DAC for more physiological pulsatile patterns. Never dose CJC-1295 with DAC daily — the extended half-life accumulates and can push IGF-1 above reference range.

How do I reconstitute ipamorelin?

Ipamorelin is supplied as a lyophilized (freeze-dried) powder. Add bacteriostatic water (BAC water) using a fresh insulin syringe — standard: 2 mL BAC water per 5 mg vial yields 2,500 mcg/mL. Draw 0.08 mL per 200 mcg dose. Store reconstituted vials refrigerated (2–8°C) and use within 30 days. Label the vial with the reconstitution date.

What labs should I monitor on ipamorelin?

Check IGF-1 at baseline, 6–8 weeks into your cycle, and at cycle end. Also check fasting glucose, fasting insulin, CBC, and CMP at baseline and cycle end. Target IGF-1 in the upper-normal range for your age — not above the reference range. Elevated fasting glucose, water retention, or joint aches warrant a dose review with your prescribing provider.

How does ipamorelin compare to sermorelin?

Ipamorelin is a GHRP (ghrelin receptor agonist) while sermorelin is a GHRH analogue (GHRH receptor agonist) — complementary pathways. Sermorelin is generally considered more physiological because it mimics endogenous GHRH. Ipamorelin produces a more potent GH pulse per injection due to its GHRP mechanism. Many protocols stack them or combine ipamorelin with CJC-1295 (another GHRH analogue) for dual-pathway benefit. See our sermorelin vs ipamorelin vs CJC-1295 comparison.